Switzerland Thomas F. Schmidt, country manager of Roche Pharma in its home market of Switzerland discusses adjusting to his first role in general management, the particularities of the Swiss market, and how Roche is aiming to be a key player in Switzerland’s digitalisation push. At Roche, we are looking at…
Switzerland Andrea Emilio Rizzoli of the Dalle Molle Institute for Artificial Intelligence, among the top 10 in the world in its field of research, outlines the focus of the Institute today, the synergies between AI and healthcare, and how pharma companies might structure their AI investments in the future. When…
Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download. Long heralded as an innovation powerhouse able to hold its own against the…
Switzerland hystrix medical is an online contracting marketplace for medical devices and replenishing/repeat purchase products in hospitals. CEO Philippe Hügli explains the company’s origins and model today, his ambitions beyond the company’s home market of Switzerland, and why a digital sales approach is core to “360-degree customer centricity.” The consumer…
Switzerland Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into a commercial-stage outfit –, and the strategy he has put in place moving forward. O’Callaghan also shares his insights on…
Switzerland In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s…
Switzerland Dr Nicolas Fischer introduces Light Chain Bioscience, a Swiss biotech company focusing on the discovery and development of bispecific antibodies using proprietary technology. Fischer also outlines the competitiveness of Light Chain’s platform, the company’s partnership strategy, and his goals for future growth. There is no question that bispecific and…
Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from – and…
Switzerland After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her own research lab, Professor Susan M. Gasser was appointed director of the Foundation of the Swiss Institute for Experimental Cancer (ISREC), in a way closing the…
Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…
Switzerland Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer modelling; and how it is looking to leverage its connections to the rest of Switzerland and to Italy. A…
Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…
See our Cookie Privacy Policy Here